Reported evidence
What the sources report
IonQ's prospectus supplement, dated October 14, 2026, offers 20,500,000 shares of common stock and 29,500,000 pre-funded warrants. Each comes with two Series C warrants, at a combined price of $40.00. J.P. Morgan is the sole underwriter.
The public offering price totals $1,999,997,050. After $10,000,000 of underwriting discounts, proceeds before expenses are $1,989,997,050. IonQ estimates net proceeds of about $1,988.5 million. These figures exclude any proceeds from exercising the warrants.
Each of the 100,000,000 Series C warrants can be exercised for one share at $69.46 until October 16, 2033. Each pre-funded warrant can be exercised for one share at $0.0001; the rest of its price is paid at purchase.
On October 13, 2026, the last reported sale price of IonQ's common stock on the New York Stock Exchange was $34.73. IonQ had 408,907,678 shares outstanding that day, a count that excludes shares that options, equity awards or outstanding warrants could add. It expects 429,407,678 shares after the offering, or 558,907,678 if the new warrants are exercised in full.
IonQ says it intends to use the net proceeds for working capital and other general corporate purposes. It may use a portion for strategic acquisitions and partnerships. It expects to deliver the securities on or about October 16, 2026.
The filing reports losses from operations of $608.8 million for the six months ended June 30, 2026, compared with $236.3 million a year earlier. IonQ's accumulated deficit was $2,256.5 million as of June 30, 2026. The filing puts IonQ's net tangible book value at $0.98 per share on June 30, 2026, or $5.48 per share as adjusted for the offering. It describes the $34.52 difference from the $40.00 offering price as immediate dilution per share for investors buying in the offering.
Sources: [1]
Our interpretation
Investor relevance — interpretation
This is a primary sale: the money goes to IonQ, not to existing holders. The 50,000,000 new shares and pre-funded warrants equal about 12% of the shares outstanding on October 13. After the offering, and if all the new warrants were also exercised, the share count would be about 37% higher in total than on that date.
The SEC's investor-education site describes a warrant as a contract giving the holder the right to buy additional shares from the company at a set price in the future. The Series C exercise price, $69.46, is exactly twice the $34.73 last reported sale price on October 13. The prospectus warns that if the share price does not exceed that exercise price on the exercise date, the Series C warrants may not have any value.
The $40.00 combined price buys a share or pre-funded warrant plus two warrants, so it is not a plain share price. It is about 15% above that October 13 price.
A raise adds resources but does not show technical or commercial progress. The filing says IonQ cannot specify with certainty how it will use the proceeds. It also lists a completed acquisition, SkyWater, on July 31, 2026, and a pending one, Elisity, agreed on October 9. IonQ would pay for Elisity in its own shares: $1.15 billion in value at closing, subject to adjustments, and up to $150 million more if revenue milestones are met through January 31, 2028. This brief does not estimate how long the cash will last; the next quarterly cash-flow statement will show how much cash operations used.
Our interpretation
What this does not establish
The offering had not closed when the supplement was filed; delivery is expected on or about October 16, 2026. The final investors are not named. J.P. Morgan is committed to buy all the securities if it buys any, and proposes to offer them to the public.
The filing-fee table lists $6,946,000,000 for the shares behind the Series C warrants: 100,000,000 shares at $69.46. That is a maximum used to calculate SEC fees, not expected cash. Holders decide whether to exercise, the warrants can expire unexercised, and in some circumstances exercise can be cashless.
The size of a raise says nothing by itself about IonQ's technology, revenue or competitive position. This brief does not forecast the share price or recommend an investment.
Background
Evidence date and disclosure
Evidence event date: 2026-10-14. The final prospectus supplement and its filing-fee table were opened on SEC EDGAR on 2026-10-14. All offering terms are IonQ's own disclosures; the prospectus notes that the SEC has not approved the securities or passed upon the document's accuracy. The warrant definition comes from an SEC investor bulletin about SPACs; the definition itself is general. Percentages and price comparisons are this publication's arithmetic from the filed figures. The publisher may hold positions in companies covered; see Disclosures.
A few useful terms
Warrant
A contract giving the holder the right to buy additional shares from the company at a set price in the future, as the SEC's investor-education site defines it.
Net tangible book value
Total assets minus liabilities and intangible assets, as the prospectus defines it.
Pre-funded warrant
A warrant whose price is paid almost entirely at purchase. In this offering, $0.0001 per share remains payable on exercise.
Prospectus supplement
A filing that sets the terms of a specific offering under an earlier base prospectus. This one supplements IonQ's prospectus dated February 26, 2025.
Underwriter
A bank that buys securities from the issuer and offers them to investors. Here, J.P. Morgan Securities LLC is the sole underwriter.
Follow the evidence
Sources & further reading
- Prospectus Supplement (To Prospectus dated February 26, 2025): 20,500,000 shares of common stock, 100,000,000 warrants and 29,500,000 pre-funded warrants
- Calculation of Filing Fee Tables
Exhibit filed with the October 14, 2026 prospectus supplement under the same EDGAR accession, 0001193125-26-421074.
- What You Need to Know About SPACs – Updated Investor Bulletin
Cited only for its general definition of a warrant.
Keep asking good questions.
Back to the reading room